Merck Folds In Schering-Plough, Begins Job Cuts
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck will cut 15,000 jobs in the first phase of a restructuring program intended to integrate Schering-Plough and save $2.6 billion to $3 billion by 2012.
You may also be interested in...
Pfizer Lowers Targeted Revenues For 2012; Wall Street Remains Skeptical
With the Wyeth integration well under way, Pfizer did what analysts claimed it was going to do for months - it lowered its 2012 revenue targets to $66 billion-$68.5 billion from $70 billion, the figure it initially projected when it announced the Wyeth merger a year ago. But these figures still tower above Wall Street's expectations
Merck’s Heart Failure Drug Flunks Phase III
Rolofylline fails to meet primary and secondary endpoints in a Phase III trial.
Merck/Schering: The Next Wave Of Consolidation
$41.1 bil. acquisition will create a cardiovascular powerhouse, buffer Merck against patent expirations of Singulair, Cozaar/Hyzaar and generate $3.5 bil in savings.